Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biologics Reached Record Share Of Novel Approvals In 2009

Executive Summary

The pharmaceutical industry's strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA's novel approvals in 2009

You may also be interested in...

Follow-on Biologic's Day Will Come - Post 2015, Teva Says

The generic giant acknowledges biogenerics as a major growth driver, but probably not before 2015.

Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers

Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class

H1N1 Vaccines Get Green Light In U.S., But Is Anything Else Needed?

Here comes the swine flu again, but this time tens of millions of people could be immunized thanks to the first round of vaccines due in mid-October

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts